Cargando…

The cross-talk of lung and heart complications in COVID-19: Endothelial cells dysfunction, thrombosis, and treatment

The pandemic respiratory illness SARS-CoV-2 has increasingly been shown to be a systemic disease that can also have profound impacts on the cardiovascular system. Although associated cardiopulmonary sequelae can persist after infection, the link between viral infection and these complications remain...

Descripción completa

Detalles Bibliográficos
Autores principales: Liu, Langjiao, Jing, Haijiao, Wu, Xiaoming, Xiang, Mengqi, Novakovic, Valerie A., Wang, Shuye, Shi, Jialan
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Frontiers Media S.A. 2022
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9390946/
https://www.ncbi.nlm.nih.gov/pubmed/35990983
http://dx.doi.org/10.3389/fcvm.2022.957006
_version_ 1784770761742876672
author Liu, Langjiao
Jing, Haijiao
Wu, Xiaoming
Xiang, Mengqi
Novakovic, Valerie A.
Wang, Shuye
Shi, Jialan
author_facet Liu, Langjiao
Jing, Haijiao
Wu, Xiaoming
Xiang, Mengqi
Novakovic, Valerie A.
Wang, Shuye
Shi, Jialan
author_sort Liu, Langjiao
collection PubMed
description The pandemic respiratory illness SARS-CoV-2 has increasingly been shown to be a systemic disease that can also have profound impacts on the cardiovascular system. Although associated cardiopulmonary sequelae can persist after infection, the link between viral infection and these complications remains unclear. There is now a recognized link between endothelial cell dysfunction and thrombosis. Its role in stimulating platelet activation and thrombotic inflammation has been widely reported. However, the procoagulant role of microparticles (MPs) in COVID-19 seems to have been neglected. As membrane vesicles released after cell injury or apoptosis, MPs exert procoagulant activity mainly by exposing phosphatidylserine (PS) on their lipid membranes. It can provide a catalytic surface for the assembly of the prothrombinase complex. Therefore, inhibiting PS externalization is a potential therapeutic strategy. In this paper, we describe the pathophysiological mechanism by which SARS-CoV-2 induces lung and heart complications through injury of endothelial cells, emphasizing the procoagulant effect of MPs and PS, and demonstrate the importance of early antithrombotic therapy. In addition, we will detail the mechanisms underlying hypoxia, another serious pulmonary complication related to SARS-CoV-2-induced endothelial cells injury and discuss the use of oxygen therapy. In the case of SARS-CoV-2 infection, virus invades endothelial cells through direct infection, hypoxia, imbalance of the RAAS, and cytokine storm. These factors cause endothelial cells to release MPs, form MPs storm, and eventually lead to thrombosis. This, in turn, accelerates hypoxia and cytokine storms, forming a positive feedback loop. Given the important role of thrombosis in the disease, early antithrombotic therapy is an important tool for COVID-19. It may maintain normal blood circulation, accelerating the clearance of viruses, waning the formation of MPs storm, and avoiding disease progression.
format Online
Article
Text
id pubmed-9390946
institution National Center for Biotechnology Information
language English
publishDate 2022
publisher Frontiers Media S.A.
record_format MEDLINE/PubMed
spelling pubmed-93909462022-08-20 The cross-talk of lung and heart complications in COVID-19: Endothelial cells dysfunction, thrombosis, and treatment Liu, Langjiao Jing, Haijiao Wu, Xiaoming Xiang, Mengqi Novakovic, Valerie A. Wang, Shuye Shi, Jialan Front Cardiovasc Med Cardiovascular Medicine The pandemic respiratory illness SARS-CoV-2 has increasingly been shown to be a systemic disease that can also have profound impacts on the cardiovascular system. Although associated cardiopulmonary sequelae can persist after infection, the link between viral infection and these complications remains unclear. There is now a recognized link between endothelial cell dysfunction and thrombosis. Its role in stimulating platelet activation and thrombotic inflammation has been widely reported. However, the procoagulant role of microparticles (MPs) in COVID-19 seems to have been neglected. As membrane vesicles released after cell injury or apoptosis, MPs exert procoagulant activity mainly by exposing phosphatidylserine (PS) on their lipid membranes. It can provide a catalytic surface for the assembly of the prothrombinase complex. Therefore, inhibiting PS externalization is a potential therapeutic strategy. In this paper, we describe the pathophysiological mechanism by which SARS-CoV-2 induces lung and heart complications through injury of endothelial cells, emphasizing the procoagulant effect of MPs and PS, and demonstrate the importance of early antithrombotic therapy. In addition, we will detail the mechanisms underlying hypoxia, another serious pulmonary complication related to SARS-CoV-2-induced endothelial cells injury and discuss the use of oxygen therapy. In the case of SARS-CoV-2 infection, virus invades endothelial cells through direct infection, hypoxia, imbalance of the RAAS, and cytokine storm. These factors cause endothelial cells to release MPs, form MPs storm, and eventually lead to thrombosis. This, in turn, accelerates hypoxia and cytokine storms, forming a positive feedback loop. Given the important role of thrombosis in the disease, early antithrombotic therapy is an important tool for COVID-19. It may maintain normal blood circulation, accelerating the clearance of viruses, waning the formation of MPs storm, and avoiding disease progression. Frontiers Media S.A. 2022-08-05 /pmc/articles/PMC9390946/ /pubmed/35990983 http://dx.doi.org/10.3389/fcvm.2022.957006 Text en Copyright © 2022 Liu, Jing, Wu, Xiang, Novakovic, Wang and Shi. https://creativecommons.org/licenses/by/4.0/This is an open-access article distributed under the terms of the Creative Commons Attribution License (CC BY). The use, distribution or reproduction in other forums is permitted, provided the original author(s) and the copyright owner(s) are credited and that the original publication in this journal is cited, in accordance with accepted academic practice. No use, distribution or reproduction is permitted which does not comply with these terms.
spellingShingle Cardiovascular Medicine
Liu, Langjiao
Jing, Haijiao
Wu, Xiaoming
Xiang, Mengqi
Novakovic, Valerie A.
Wang, Shuye
Shi, Jialan
The cross-talk of lung and heart complications in COVID-19: Endothelial cells dysfunction, thrombosis, and treatment
title The cross-talk of lung and heart complications in COVID-19: Endothelial cells dysfunction, thrombosis, and treatment
title_full The cross-talk of lung and heart complications in COVID-19: Endothelial cells dysfunction, thrombosis, and treatment
title_fullStr The cross-talk of lung and heart complications in COVID-19: Endothelial cells dysfunction, thrombosis, and treatment
title_full_unstemmed The cross-talk of lung and heart complications in COVID-19: Endothelial cells dysfunction, thrombosis, and treatment
title_short The cross-talk of lung and heart complications in COVID-19: Endothelial cells dysfunction, thrombosis, and treatment
title_sort cross-talk of lung and heart complications in covid-19: endothelial cells dysfunction, thrombosis, and treatment
topic Cardiovascular Medicine
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9390946/
https://www.ncbi.nlm.nih.gov/pubmed/35990983
http://dx.doi.org/10.3389/fcvm.2022.957006
work_keys_str_mv AT liulangjiao thecrosstalkoflungandheartcomplicationsincovid19endothelialcellsdysfunctionthrombosisandtreatment
AT jinghaijiao thecrosstalkoflungandheartcomplicationsincovid19endothelialcellsdysfunctionthrombosisandtreatment
AT wuxiaoming thecrosstalkoflungandheartcomplicationsincovid19endothelialcellsdysfunctionthrombosisandtreatment
AT xiangmengqi thecrosstalkoflungandheartcomplicationsincovid19endothelialcellsdysfunctionthrombosisandtreatment
AT novakovicvaleriea thecrosstalkoflungandheartcomplicationsincovid19endothelialcellsdysfunctionthrombosisandtreatment
AT wangshuye thecrosstalkoflungandheartcomplicationsincovid19endothelialcellsdysfunctionthrombosisandtreatment
AT shijialan thecrosstalkoflungandheartcomplicationsincovid19endothelialcellsdysfunctionthrombosisandtreatment
AT liulangjiao crosstalkoflungandheartcomplicationsincovid19endothelialcellsdysfunctionthrombosisandtreatment
AT jinghaijiao crosstalkoflungandheartcomplicationsincovid19endothelialcellsdysfunctionthrombosisandtreatment
AT wuxiaoming crosstalkoflungandheartcomplicationsincovid19endothelialcellsdysfunctionthrombosisandtreatment
AT xiangmengqi crosstalkoflungandheartcomplicationsincovid19endothelialcellsdysfunctionthrombosisandtreatment
AT novakovicvaleriea crosstalkoflungandheartcomplicationsincovid19endothelialcellsdysfunctionthrombosisandtreatment
AT wangshuye crosstalkoflungandheartcomplicationsincovid19endothelialcellsdysfunctionthrombosisandtreatment
AT shijialan crosstalkoflungandheartcomplicationsincovid19endothelialcellsdysfunctionthrombosisandtreatment